EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
Clinical trials for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) explained in plain language.
Never miss a new study
Get alerted when new EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) trials appear
Sign up with your email to follow new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare blood disorders: benralizumab trial launches
Disease control Recruiting nowThis Phase 3 trial tests the drug benralizumab (Fasenra) in children aged 6 to 17 with two rare eosinophilic diseases: EGPA and HES. The study aims to see if the drug is safe, how it works in the body, and whether it can help control the disease. Fourteen children will receive in…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Pregnancy and vasculitis: new study seeks answers
Knowledge-focused Recruiting nowThis study tracks the pregnancy experiences of women with vasculitis, a group of rare diseases causing blood vessel inflammation. Researchers will use online surveys to understand how vasculitis affects pregnancy and what outcomes occur. The goal is to gather information to help …
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Skin biopsies shed light on rare blood vessel disease
Knowledge-focused Recruiting nowThis study looks at skin samples from 50 people with different types of vasculitis, a condition where blood vessels become inflamed. Researchers want to understand how the disease affects the skin at a molecular level. Participants must have an active skin rash related to their v…
Matched conditions: EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)
Sponsor: Peter Merkel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC